189 related articles for article (PubMed ID: 36113495)
1. Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study.
Schott Andersen AS; Maarbjerg S; Noory N; Heinskou TB; Forman JL; Cruccu G; Ashina M; Bendtsen L
Lancet Neurol; 2022 Nov; 21(11):994-1003. PubMed ID: 36113495
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
Zakrzewska JM; Palmer J; Morisset V; Giblin GM; Obermann M; Ettlin DA; Cruccu G; Bendtsen L; Estacion M; Derjean D; Waxman SG; Layton G; Gunn K; Tate S;
Lancet Neurol; 2017 Apr; 16(4):291-300. PubMed ID: 28216232
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
Dodick DW; Goadsby PJ; Spierings EL; Scherer JC; Sweeney SP; Grayzel DS
Lancet Neurol; 2014 Sep; 13(9):885-92. PubMed ID: 25127173
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study.
Ashina H; Iljazi A; Al-Khazali HM; Eigenbrodt AK; Larsen EL; Andersen AM; Hansen KJ; Bräuner KB; Mørch-Jessen T; Chaudhry B; Antic S; Christensen CE; Ashina M; Amin FM; Schytz HW
J Headache Pain; 2020 Jun; 21(1):62. PubMed ID: 32493206
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Edvinsson L; Rapoport AM; Lipton RB; Spierings EL; Diener HC; Burstein R; Loupe PS; Ma Y; Yang R; Silberstein SD
Lancet Neurol; 2015 Nov; 14(11):1091-100. PubMed ID: 26432181
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
[TBL] [Abstract][Full Text] [Related]
9. Migraine induction with calcitonin gene-related peptide in patients from erenumab trials.
Christensen CE; Younis S; Deen M; Khan S; Ghanizada H; Ashina M
J Headache Pain; 2018 Nov; 19(1):105. PubMed ID: 30409109
[TBL] [Abstract][Full Text] [Related]
10. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Yu S; Kim BK; Wang H; Zhou J; Wan Q; Yu T; Lian Y; Arkuszewski M; Ecochard L; Wen S; Yin F; Li Z; Su W; Wang SJ
J Headache Pain; 2022 Nov; 23(1):146. PubMed ID: 36404301
[TBL] [Abstract][Full Text] [Related]
11. Botulinum neurotoxin type A in the treatment of classical Trigeminal Neuralgia (BoTN): study protocol for a randomized controlled trial.
Burmeister J; Holle D; Bock E; Ose C; Diener HC; Obermann M
Trials; 2015 Dec; 16():550. PubMed ID: 26634453
[TBL] [Abstract][Full Text] [Related]
12. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
13. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
Dodick DW; Goadsby PJ; Schwedt TJ; Lipton RB; Liu C; Lu K; Yu SY; Severt L; Finnegan M; Trugman JM
Lancet; 2023 Dec; 402(10419):2307-2316. PubMed ID: 37979595
[TBL] [Abstract][Full Text] [Related]
14. Erenumab for Treatment of Persistent Erythema and Flushing in Rosacea: A Nonrandomized Controlled Trial.
Wienholtz NKF; Christensen CE; Do TP; Frifelt LEW; Snellman J; Lopez-Lopez CL; Egeberg A; Thyssen JP; Ashina M
JAMA Dermatol; 2024 Jun; 160(6):612-619. PubMed ID: 38630457
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.
Yu S; Kim BK; Guo A; Kim MH; Zhang M; Wang Z; Liu J; Moon HS; Tan G; Yang Q; McGrath D; Hanna M; Stock DA; Gao Y; Croop R; Lu Z
Lancet Neurol; 2023 Jun; 22(6):476-484. PubMed ID: 37210098
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
17. Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial.
Schett G; Bainbridge C; Berkowitz M; Davy K; Fernandes S; Griep E; Harrison S; Gupta A; Lloyd-Hughes J; Roberts A; Layton M; Nowak NA; Patel J; Rech J; Smith JE; Watts S; Tak PP
Lancet Rheumatol; 2020 Oct; 2(10):e623-e632. PubMed ID: 38273625
[TBL] [Abstract][Full Text] [Related]
18. A Controlled Trial of Erenumab for Episodic Migraine.
Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821
[TBL] [Abstract][Full Text] [Related]
19. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
Cullum CK; Do TP; Ashina M; Bendtsen L; Hugger SS; Iljazi A; Gusatovic J; Snellman J; Lopez-Lopez C; Ashina H; Amin FM
J Headache Pain; 2022 Jun; 23(1):61. PubMed ID: 35655137
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.
Sun H; Dodick DW; Silberstein S; Goadsby PJ; Reuter U; Ashina M; Saper J; Cady R; Chon Y; Dietrich J; Lenz R
Lancet Neurol; 2016 Apr; 15(4):382-90. PubMed ID: 26879279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
